Paulo Naud

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

Jorma Paavonen, Paulo Naud, Jorge Salmerón et al. · The Lancet · 2009 · 1.7K citations

Medicine, Gynecology, Oncology +17

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

Diane M. Harper, Eduardo L. Franco, Cosette M. Wheeler et al. · The Lancet · 2004 · 1.6K citations

Veterinary Medicine, Infectious Diseases, Preventive Medicine +16

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

Jorma Paavonen, David Jenkins, F. Xavier Bosch et al. · The Lancet · 2007 · 1.3K citations

Veterinary Medicine, Immunology, Oncology +17

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

Matti Lehtinen, Jorma Paavonen, Cosette M. Wheeler et al. · The Lancet Oncology · 2011 · 703 citations

Medicine, Gynecology, Oncology +15

Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

Cosette M. Wheeler, Xavier Castellsagué, Suzanne M. Garland et al. · The Lancet Oncology · 2011 · 507 citations

Medicine, Immunology, Infectious Diseases +17